Lisavanbulin is under clinical development by Basilea Pharmaceutica and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Glioblastoma Multiforme (GBM) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lisavanbulin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Lisavanbulin overview

Lisavanbulin (BAL-101553) is under development for the treatment of advanced or recurrent solid tumors including colorectal cancer, gastric or cancers of the gastro-esophageal junction, non-small cell lung cancer, ovarian cancer, pancreatic cancer (including ampullary), triple-negative breast cancer, fallopian tube cancer, primary peritoneal cancer, endometrial cancer, malignant glioma and recurrent glioblastoma multiforme. It is administered through oral and intravenous routes. BAL101553 is a highly water soluble lysine prodrug of the synthetic small molecule BAL27862. It is a small molecule drug with a dual mode of action, targeting intracellular microtubules and in addition blocking the tumor blood supply.

It was also under development for the treatment of glioblastoma multiforme.

Basilea Pharmaceutica overview

Basilea Pharmaceutica (Basilea) is a biopharmaceutical company that develops and markets antibiotics, antifungals and oncology drugs. The company products are for increasing resistance and non-response to present treatment options for various therapeutic areas such as cancer, bacterial infections, and fungal infections. Basilea also conducts research in the areas of anti-infectives, cancer, and bacterial or fungal strains. It discovers drugs with the help of various technologies such as genomics, assay development, cell biology and others. The company also operates in France, the UK, China, Germany, Spain, Switzerland, Italy, and Denmark. Basilea is headquartered in Basel, Switzerland.

For a complete picture of Lisavanbulin’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.